Relacorilant (RELA) with nab-paclitaxel (NP): Safety and activity in patients with pancreatic ductal adenocarcinoma (PDAC) and ovarian cancer (OvCA).
2019
4130Background:
Glucocorticoid receptor(GR) pathway activation has been linked with chemotherapy resistance (CTR).
RELA(formerly CORT125134, Corcept Therapeutics), a potent selective GR modulator...
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
2
Citations
NaN
KQI